PRKAA2 and hepatocellular carcinoma: Interestingly, aldometanib did not suppress the development of HCC in liver lacking AMPK (Fig. 2a, b; Supplementary information, Fig. S6a–f), indicating that aldometanib indeed suppresses HCC progression by activating AMPK.